The Hypersecretory Conditions drugs in development market research report provides comprehensive information on the therapeutics under development for Hypersecretory Conditions, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hypersecretory Conditions. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hypersecretory Conditions and features dormant and discontinued products.
GlobalData tracks nine drugs in development for Hypersecretory Conditions by nine companies/universities/institutes. The top development phase for Hypersecretory Conditions is phase ii with four drugs in that stage. The Hypersecretory Conditions pipeline has nine drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Hypersecretory Conditions pipeline products market are: Blueprint Medicines, MacroGenics and AB Science.
The key targets in the Hypersecretory Conditions pipeline products market include Mast/Stem Cell Growth Factor Receptor Kit, Interleukin 3 Receptor Subunit Alpha, and Platelet Derived Growth Factor Receptor Alpha.
The key mechanisms of action in the Hypersecretory Conditions pipeline product include Mast/Stem Cell Growth Factor Receptor Kit Inhibitor with four drugs in Phase III. The Hypersecretory Conditions pipeline products include four routes of administration with the top ROA being Oral and five key molecule types in the Hypersecretory Conditions pipeline products market including Small Molecule, and Antisense Oligonucleotide.
Hypersecretory Conditions overview
Hypersecretory Condition is a group of disorders characterized by hypersecretion of gastric acid also known as hypergastrinemia. This condition can result in peptic ulcers, GERD, gastrointestinal hemorrhage causing a predominant mortality and morbidity. Underlying diseases, helicobacter pylori infection, gastric outlet obstruction, chronic renal failure and idiopathic causes results to hypersecretion of gastric juice. Diagnosed by the gastrin levels and gastric acid secretion range. Proton pump inhibitors are first line of therapy followed by antibiotics in H. Pylori infections, and supportive care and diet balance by avoiding foods that are citrus in nature. Surgical options in complicated cases.
For a complete picture of Hypersecretory Conditions’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
